Thiogenesis Therapeutics, Corp. (TTI.V)
- Newsfile
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound TTI-
- Newsfile
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement, originally announced on November 20, 2023 (the "Offering"). Under this second tranche, the Company has issued 417,000 common shares for gross proceeds of C$312,750. The Company paid cash ...
